within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BC09_Tegoprazan;

model Tegoprazan
  extends Pharmacolibrary.Drugs.ATC.A.A02BC09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BC09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tegoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. It is approved for clinical use in several countries, particularly in East Asia, as an alternative to proton pump inhibitors for acid suppression.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult male volunteers (mean age 26 years) after single oral administration of tegoprazan.</p><h4>References</h4><ol><li><p>Han, S, et al., &amp; Bae, KS (2021). Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. <i>Clinical therapeutics</i> 43(8) 1371–1380. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2021.06.007\">10.1016/j.clinthera.2021.06.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34246485/\">https://pubmed.ncbi.nlm.nih.gov/34246485</a></p></li><li><p>He, J, et al., &amp; Chen, S (2021). Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 41(1) 89–97. DOI:<a href=\"https://doi.org/10.1007/s40261-020-00986-4\">10.1007/s40261-020-00986-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33355910/\">https://pubmed.ncbi.nlm.nih.gov/33355910</a></p></li><li><p>Han, S, et al., &amp; Bae, KS (2019). Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. <i>Alimentary pharmacology &amp; therapeutics</i> 50(7) 751–759. DOI:<a href=\"https://doi.org/10.1111/apt.15438\">10.1111/apt.15438</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31437865/\">https://pubmed.ncbi.nlm.nih.gov/31437865</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tegoprazan;
